ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

Idenix: 89% of Patients in Hep C Trial Arm Achieved Viral Suppression

By Ben Fox Rubin Biopharmaceutical firm Idenix Pharmaceuticals Inc. (IDIX) has provided some results from an ongoing Phase 2b study of its lead hepatitis C drug, IDX184, showing positive suppression of the virus. Shares jumped 15% after hours Tuesday to $10.79, as the company's stock often moves sharply following reports related to its or its competitors' hepatitis C drugs. As of the market close, the shares were up 26% so far this year. Idenix is among a handful of companies scrabbling to develop a marketable all-oral Hepatitis C drug, with demand for the treatment expected to be worth billions of dollars a year. Gilead Sciences Inc. (GILD) is a main competitor of Idenix in the race develop such a drug; it spent $11 billion to buy Pharmasset this year, in part to obtain its lead hepatitis C drug candidate, GS-7977. In the Idenix study, Idenix used a mix of its IDX184 with older medications interferon and ribavirin. In all, 31 patients were enrolled and 18 reached extended rapid virologic response, which is when the virus becomes undetectable at four weeks of treatment and again at 12 weeks of treatment. Of those 18 patients, nine were given additional treatments for 12 more weeks. All but one of them achieved sustained virologic response, or undetectable traces of the virus, a month after treatment ended. The other nine patients and those who didn't reach extended rapid virologic response are continuing a regimen of 36 weeks of treatment. Write to Ben Fox Rubin at ben.rubin@dowjones.com

Stock News for Gilead Sciences (GILD)
DateTimeHeadline
04/28/201510:59:12Bristol-Myers Squibb Crushes First-Quarter Earnings: Here's Why
04/28/201509:58:39Aetna Boosts Profit Outlook -- Update
04/28/201507:30:41Aetna Boosts Profit Outlook
04/28/201507:17:023 Things to Watch with Gilead Sciences Inc.'s Q1 Earnings
04/28/201507:07:51Aetna Boosts Profit Outlook
04/27/201515:19:29Needham & Company LLC Analysts Give Gilead Sciences a $120.00...
04/27/201513:03:02Biotech Bubble Bursting? 3 Stocks I Want to Buy
04/27/201510:10:09Bristol-Myers Hepatitis C Therapy With Sovaldi Meets Study Goals
04/27/201509:46:17Bristol-Myers Hepatitis C Therapy With Sovaldi Meets Study Goals
04/27/201504:58:43Gilead Sciences Now Covered by Oppenheimer (GILD)
04/26/201513:02:02Can You Guess Which State Won't Pay for Hepatitis C Drugs?
04/26/201509:17:43MARKET SNAPSHOT: Apple, Energy, Health Care Earnings To Dominate...
04/26/201508:01:02Why Healthcare is the Best Sector For Your Money
04/26/201505:47:00Gilead gibt Ergebnisse aus Studien zu auf Sofosbuvir basierenden...
04/25/201522:14:00Gilead annonce les résultats d'études évaluant des traitements à...
04/25/201522:14:00Gilead comunica i risultati derivati dagli studi condotti ai...
04/25/201501:00:00Gilead Announces Results From Studies Evaluating Sofosbuvir-Based...
04/24/201515:46:50Gilead Sciences Stock Rating Reaffirmed by Morgan Stanley (GILD)
04/24/201510:48:12Correction to Merck Hepatitis C Treatment Story Update
04/24/201510:26:22Merck: Hepatitis C Treatment Shows 95% Cure Rate -- Update

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad